Corient Private Wealth
EWTX icon

Corient Private Wealth’s Edgewise Therapeutics EWTX Stock Holding History

Corient Private Wealth’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$502K Buy
+12,365
New +$426K ﹤0.01% 2226

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Corient Private Wealth's EWTX Position: Q2 2026 in Review

Corient Private Wealth opened a new position in Edgewise Therapeutics (EWTX) in Q2 2026: 12,365 shares worth $502K. The stake represents ﹤0.01% of the portfolio and ranks #2226 among its holdings.

223 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Corient Private Wealth held 12,365 shares of Edgewise Therapeutics worth $502K as of Q2 2026.
  • Edgewise Therapeutics was a new Corient Private Wealth position in Q2 2026.
  • Edgewise Therapeutics made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #2226 holding.
  • 223 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.